Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

RETRACTED ARTICLE: AI finds microbial signatures in tumours and blood across cancer types

Analysis of nucleic-acid sequences from human cancers, along with samples from adjacent tissue and blood, reveals the presence of microorganisms in tumours and blood across cancers.
By
  1. Nadim J. Ajami

    1. Nadim J. Ajami is in the Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

  2. Jennifer A. Wargo

    1. Jennifer A. Wargo is in the Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA, and in the Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center.

The world is filled with microorganisms, which have a profound impact on many facets of life. Do these microbial communities influence cancer1? Many studies of microbes and their genomes (collectively called the microbiome) have focused on the gut, where most of the body’s microbes reside. This work has revealed a role for the gut microbiome in several types of cancer that arise in the intestinal lining itself2–4, and indicated that the gut microbiome might influence cancers at distant sites through its impact on the immune system1. In addition, emerging evidence indicates that microbial signatures (such as nucleic acids) can be found in tumours at other sites in the body5,6 and in the tissues and blood of individuals who don’t have cancer7,8. Writing in Nature, Poore et al.9 build on this evidence, identifying signatures of microbial DNA and RNA, both in tumours and in the blood, across multiple human cancers. The authors further suggest that these signatures might augment existing clinical diagnostic tools, although further work is needed in this area.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 579, 502-503 (2020)

doi: https://doi.org/10.1038/d41586-020-00637-w

Updates & Corrections

  • Retraction 03 July 2024: In view of the fact that the authors of ‘Microbiome analyses of blood and tissues suggest cancer diagnostic approach’ (G. D. Poore et al. Nature 579, 567–574; 2020) are retracting their report, Nadim J. Ajami and Jennifer A. Wargo, the authors of the News & Views article ‘AI finds microbial signatures in tumours and blood across cancer types’, which dealt with this study and was based on the accuracy and reproducibility of the data, are retracting their article.

References

  1. Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V. & Wargo, J. A. Nature Med. 25, 377–388 (2019).

    Article  PubMed  Google Scholar 

  2. Dejea, C. M. et al. Proc. Natl Acad. Sci. USA 111, 18321–18326 (2014).

    Article  PubMed  Google Scholar 

  3. Kostic, A. D. et al. Cell Host Microbe 14, 207–215 (2013).

    Article  PubMed  Google Scholar 

  4. Marshall, B. J. & Warren, J. R. Lancet 323, 1311–1315 (1984).

    Article  Google Scholar 

  5. Bullman, S. et al. Science 358, 1443–1448 (2017).

    Article  PubMed  Google Scholar 

  6. Robinson, K. M., Crabtree, J., Mattick, J. S. A., Anderson, K. E. & Dunning Hotopp, J. C. Microbiome 5, 9 (2017).

    Article  PubMed  Google Scholar 

  7. Nakatsuji, T. et al. Nature Commun. 4, 1431 (2013).

    Article  PubMed  Google Scholar 

  8. Whittle, E., Leonard, M. O., Harrison, R., Gant, T. W. & Tonge, D. P. Front. Microbiol. 9, 3266 (2018).

    Article  PubMed  Google Scholar 

  9. Poore, G. D. et al. Nature 579, 567–574 (2020).

    Article  Google Scholar 

  10. Geller, L. T. et al. Science 357, 1156–1160 (2017).

    Article  PubMed  Google Scholar 

  11. Riquelme, E. et al. Cell 178, 795–806 (2019).

    Article  PubMed  Google Scholar 

  12. Sethi, V. et al. Gastroenterology 155, 33–37 (2018).

    Article  PubMed  Google Scholar 

  13. Wilson, B. E., Routy, B., Nagrial, A. & Chin, V. T. Cancer Immunol. Immunother. 69, 343–354 (2020).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

J.A.W. is an inventor on a US patent application (PCT/US17/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance immune checkpoint blockade responses by modulating the microbiome. J.A.W. reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, Exelixis, and Bristol-Myers Squibb. J.A.W. serves as a consultant / advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals and Microbiome DX. J.A.W. also receives research support from GlaxoSmithKline, Roche/Genentech, Bristol-Myers Squibb, and Novartis.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links